AURA — Aura Biosciences, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1501796 ·
Last close
$7.15
Market Cap
$744.13M
52W High
$9.53
52W Low
$4.73
ADV30
850,440
Next earnings
2026-11-09
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -35,062,000 -32,066,000 321,617,000 41,669,000 34,190,000
Jun 2026 0 — -48,069,000 -45,637,000 348,129,000 67,836,000 32,862,000
Mar 2026 0 — -34,866,000 -33,685,000 137,677,000 84,793,000 30,430,000
Dec 2025 0 — -27,237,000 -25,559,000 169,430,000 59,515,000 32,517,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-109,303,000
Investing CF
$-141,199,000
Financing CF
$245,025,000
CapEx
$-379,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.67
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-591,806,000
Inventory
—
Receivables
$1,871,000
ST Investments
$255,564,000
EBIT TTM
$-145,234,000
Pretax Income TTM
$-136,854,000
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -112,791,000 -106,191,000 169,430,000 32,517,000 136,913,000 -84,742,000
Dec 2024 0 -96,116,000 -86,919,000 182,503,000 30,533,000 151,970,000 -79,805,000
Dec 2023 0 -84,991,000 -76,408,000 255,075,000 29,227,000 225,848,000 -63,847,000
Dec 2022 0 -60,295,000 -58,763,000 223,935,000 28,352,000 195,583,000 -54,601,000

TTM Snapshot

Revenues TTM
$153,817,000
NetIncome TTM
$-131,011,000
OpCashFlow TTM
—
Assets (Latest)
$348,129,000
Forward EPS
$-2.03

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $7.14 · call volume: 13 · put volume: 1

Peers — same industry

TickerNameMarket CapLastDaily %
GLUE Monte Rosa Therapeutics, Inc. $775.03M $9.07 —
SLDB Solid Biosciences Inc. $695.33M $6.23 —
ATTO Attovia Therapeutics, Inc. $679.29M $14.86 —
IAM Iambic Therapeutics, Inc. $674.04M $14.22 —
MGTX MeiraGTx Holdings plc $826.80M $8.46 —

News headlines (Yahoo Finance, 1h cache)

OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate
2026-11-17 12:00 · Yahoo
Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade
2026-11-11 20:19 · Yahoo
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-09 12:00 · Yahoo
Aura Biosciences to Participate in Upcoming Investor Conference
2026-11-03 21:02 · Yahoo
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:28 · Yahoo
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-11 11:00 · Yahoo
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-05-04 10:03 · Yahoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-11 20:01 · Yahoo
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-05 21:15 · Yahoo
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
2026-05-04 13:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.